Ampio selects ascendia pharmaceuticals, inc. to provide cdmo services to support clinical development of oa-201

Englewood, colo. , oct. 5, 2023 /prnewswire/ -- ampio pharmaceuticals, inc. (nyse american: ampe) (the "company), a pre-revenue stage biopharmaceutical company focused on development of a potential treatment for osteoarthritis as part of its oa-201 program, today announced that it has selected ascendia pharmaceuticals, inc. ("ascendia") to provide services to support the clinical development of oa-201, a novel therapeutic for the treatment of symptomatic osteoarthritis pain.
AMPE Ratings Summary
AMPE Quant Ranking